Gorrissen Federspiel advised Andera Partners and Kurma Partners on the USD 159.8 million Series A financing of Alveus Therapeutics Inc.
Obesity is one of the fastest-growing global health challenges, and current treatments can make it difficult for patients to maintain weight loss over time.
Alveus’ lead candidate, ALV-100, and its amylin-based pipeline are being developed to deliver sustained efficacy with less frequent dosing, improved tolerability, and significantly improved body composition, aiming for more meaningful outcomes.
The core team from Gorrissen Federspiel consisted of Niels Bang and Caroline Philip.